8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Illicit drug use disorders are the most stigmatised health conditions worldwide, and stigma acts as a meaningful barrier to treatment entry and treatment provision. In the context of dramatically rising opioid-related harms, it is critical that we understand the drivers of stigma and how it affects opioid use disorder treatment and policy. The aim of this narrative review is to discuss how opioid-related stigma impacts treatment provision and harm reduction, and provide potential strategies to reduce stigma at a social and structural level. We used the Framework for Integrating Normative Influences on Stigma (FINIS) to identify sources of opioid-related stigma at the macro (structural stigma), meso (public stigma) and micro (internalised stigma) levels. Reducing stigma requires strategies that target multiple levels, however addressing inequity in the laws, regulations, and rules that segregate people with opioid and other substance use disorders from mainstream society is essential.

          Related collections

          Most cited references120

          • Record: found
          • Abstract: not found
          • Article: not found

          Neurobiologic Advances from the Brain Disease Model of Addiction.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

            Cochrane Database of Systematic Reviews
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              "A disease like any other"? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence.

              Clinicians, advocates, and policy makers have presented mental illnesses as medical diseases in efforts to overcome low service use, poor adherence rates, and stigma. The authors examined the impact of this approach with a 10-year comparison of public endorsement of treatment and prejudice. The authors analyzed responses to vignettes in the mental health modules of the 1996 and 2006 General Social Survey describing individuals meeting DSM-IV criteria for schizophrenia, major depression, and alcohol dependence to explore whether more of the public 1) embraces neurobiological understandings of mental illness; 2) endorses treatment from providers, including psychiatrists; and 3) reports community acceptance or rejection of people with these disorders. Multivariate analyses examined whether acceptance of neurobiological causes increased treatment support and lessened stigma. In 2006, 67% of the public attributed major depression to neurobiological causes, compared with 54% in 1996. High proportions of respondents endorsed treatment, with general increases in the proportion endorsing treatment from doctors and specific increases in the proportions endorsing psychiatrists for treatment of alcohol dependence (from 61% in 1996 to 79% in 2006) and major depression (from 75% in 1996 to 85% in 2006). Social distance and perceived danger associated with people with these disorders did not decrease significantly. Holding a neurobiological conception of these disorders increased the likelihood of support for treatment but was generally unrelated to stigma. Where associated, the effect was to increase, not decrease, community rejection. More of the public embraces a neurobiological understanding of mental illness. This view translates into support for services but not into a decrease in stigma. Reconfiguring stigma reduction strategies may require providers and advocates to shift to an emphasis on competence and inclusion.
                Bookmark

                Author and article information

                Journal
                Subst Abuse Rehabil
                Subst Abuse Rehabil
                sar
                Substance Abuse and Rehabilitation
                Dove
                1179-8467
                25 January 2022
                2022
                : 13
                : 1-12
                Affiliations
                [1 ]Monash Addiction Research Centre, Eastern Health Clinical School, Monash University Peninsula Campus , Frankston, Victoria, 3199, Australia
                [2 ]Turning Point, Eastern Health , Richmond, Victoria, 3121, Australia
                Author notes
                Correspondence: Suzanne Nielsen, Monash Addiction Research Centre, Eastern Health Clinical School, Monash University Peninsula Campus , 47-49 Moorooduc Hwy, Frankston, Victoria, 3199, Australia, Tel +61 3 9904 4641, Email suzanne.nielsen@monash.edu
                Author information
                http://orcid.org/0000-0002-6747-1937
                Article
                304566
                10.2147/SAR.S304566
                8800858
                35115860
                953dc8f8-0830-4d89-804d-8d01487e05a3
                © 2022 Cheetham et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 16 October 2021
                : 11 January 2022
                Page count
                Figures: 0, References: 116, Pages: 12
                Funding
                Funded by: NHMRC Grants;
                SN, LP and DL are supported by NHMRC Grants (#1163961, # 1189975 and # 1196892). LP is also the recipient of the Monash Addiction Research Centre (MARC) PhD Top Up Scholarship.
                Categories
                Review

                stigma,opioid use disorder,finis,opioid-related disorders,analgesics,opioid,social stigma

                Comments

                Comment on this article